Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

Recruiting
View on ClinicalTrials.gov →
Summary
This is a single center study enrolling up to 10 patients. The primary objective is to Evaluate the feasibility and safety of the DaRT for the treatment of Liver Metastases. The secondary objective is to evaluate the pathological response of liver metastases according to the Modified tumor regression grade\[1\] and to evaluate the radiological response of liver metastases using the RECIST criteria.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-04-23; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2023-11-06
Trial Details
NCT Number NCT05829291
Lead Sponsor Alpha Tau Medical LTD.
Conditions Liver Metastases
Enrollment 10 participants
Start Date 2023-10-01
Primary Completion 2027-02 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-16